Since last August, European regulators have been investigating reports H1N1 vaccine from GlaxoSmithKline, Pandemrix – which is not approved for use in the United States – can be linked to the disorder narcolepsy asleep in some children and adolescents.

Today, the European Medicines Agency said that while a more thorough review would probably be completed until July, in the meantime label of the vaccine should be physicians to weigh a potential narcolepsy, when considering the possibility of use of Pandemrix among children and adolescents. Early studies suggest that there may be a link, said EMA, if the data were “methodological limitations. In other words: it is too early to tell, but we do not reject it.

Here is the history of Dow Jones Newswires, who notes that there were 247 reports of cases of narcolepsy patients vaccinated with Pandemrix, which has been used outside the United States during the 2009 H1N1 pandemic. Glaxo said in a statement, that “more information must be collected on a potential risk of a causal link… before drawing conclusions can be drawn”, and it is important to wait for the results of the further consideration.

In the fall, the CDC said that it addressed if narcolepsy was associated with any H1N1 or licensed for use in the United States seasonal influenza vaccines and not found “no association.”

Narcolepsy causes periods of extreme daytime sleepiness and sleep attacks,”Pan that is inadvertent and unwanted. The WSJ reported on the fascinating history of the search dogs helped narcoleptic how advance research on the status of persons.

Image: iStockphoto

View the original article here